Lauxera closed a €520M healthtech fund in under 18 months. Here is how it did it — TFN

Lauxera Capital Partners has closed its second healthtech growth fund at €520 million, exceeding its €500 million hard cap

The firm invests between €20 and €50 million in European healthtech companies across medical devices, digital health, pharma services, and life science tools

The fund’s approach was proven in October 2025 when OrganOx, a UK portfolio company, was bought by Japan’s Terumo Group for about $1.5 billion

Lauxera Growth II reached €520 million, exceeding its €500 million hard cap, and closed in less than 18 months from its first close. This nearly doubled the size of the first fund.

The fund was oversubscribed and closed under 18 months, with more than 90% of existing limited partners reinvesting. It also attracted new investors from regions like DACH, the Nordics, Latin America, and the US.